H.C. Wainwright analyst Edward White maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a price target of $22.00. The company’s shares closed last Wednesday at $13.79.
According to TipRanks.com, White is a top 100 analyst with an average return of 31.8% and a 55.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Syndax Pharmaceuticals.
Currently, the analyst consensus on IDEAYA Biosciences is a Strong Buy with an average price target of $23.33.
Based on IDEAYA Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $12.04 million. In comparison, last year the company had a GAAP net loss of $9.57 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IDYA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.